Dan Renick, RPh


President, Precision for Value, Gladstone, NJ

Authored Items

Implications of the New Provider-Driven Value-Assessment Tools in Oncology

July 2015, Vol 6, No 6 - VBCC Perspectives

Given the number of oncology agents introduced over the past 5 years, and the corresponding rise in costs, it is little surprise that multiple organizations are reacting with methods to assess value. Although payers have historically been the default for assessing value to determine formulary coverage, the most recent entrants of the American Society of Clinical Oncology (ASCO), with its value framework, and Memorial Sloan Kettering Cancer Center (MSKCC), with its DrugAbacus, into this arena represent providers of oncology care. Historically pegged as solely focused on clinical evidence and seeking effective therapy at all costs, the focus by providers on the value of cancer care is increasing. [ Read More ]